Avacopan in the treatment of relapsing polychondritis with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis: A case report

doi:10.5527/wjn.v14.i3.109400

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

(60)

(47)

(0)

(815)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Nephrol. Sep 25, 2025; 14(3): 109400
Published online Sep 25, 2025. doi: 10.5527/wjn.v14.i3.109400

Full Size Figure Download Figure

Figure 1 Renal biopsy stained using periodic acid Schiff shows necrotizing and crescentic glomerulonephritis affecting more than 50% of the glomeruli revealing rapidly progressive glomerulonephritis.

Citation: Nguyen JT, Anand M. Avacopan in the treatment of relapsing polychondritis with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis: A case report. World J Nephrol 2025; 14(3): 109400
URL: https://www.wjgnet.com/2220-6124/full/v14/i3/109400.htm
DOI: https://dx.doi.org/10.5527/wjn.v14.i3.109400

Nguyen JT, Anand M. Avacopan in the treatment of relapsing polychondritis with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis: A case report. World J Nephrol 2025; 14(3): 109400 [PMID: 41024959 DOI: 10.5527/wjn.v14.i3.109400]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.